Merzee — Medicare Part D Spending

Generic: Norethindrone-E.Estradiol-Iron | Manufacturer: Overall

2023 Spending

$3.4K

2023 Claims

2023 Beneficiaries

N/A

Cost/Unit (2023)

$3.35

5-Year Spending Trend (2019-2023)

Year	Total Spending	Claims	Beneficiaries	Cost/Unit
2019	N/A	N/A	N/A	N/A
2020	N/A	N/A	N/A	N/A
2021	N/A	N/A	N/A	N/A
2022	N/A	N/A	N/A	N/A
2023	$3.4K	28	N/A	$3.35

5Y CAGR (cost/unit): N/AYoY Change (2022-2023): N/A

Spending by State

State	Total Drug Cost	Claims	Prescribers	Beneficiaries
South Carolina	$1.6K	12	1	N/A

📊

DrugPricePeek Editorial TeamData Specialists

The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.

✓ Sourced from CMS NADAC & Medicare Part D✓ Quarterly review✓ No paid placements

Read our full methodology or contact us with corrections.

Frequently Asked Questions

How much does Medicare spend on Merzee?

In 2023, Medicare Part D spent $3.4K on Merzee (Norethindrone-E.Estradiol-Iron), serving N/A beneficiaries across 28 claims.

What is the cost per unit of Merzee under Medicare?

The weighted average cost per dosage unit of Merzee was $3.35 in 2023. The 5-year compound annual growth rate (2019-2023) was N/A.

Who manufactures Merzee?

Merzee (generic name: Norethindrone-E.Estradiol-Iron) is manufactured by Overall. There are 1 manufacturer(s) listed in the CMS database for this drug.

Is Merzee covered by Medicare Part D?

Yes, Merzee is included in Medicare Part D spending data, indicating it is covered by Part D plans. However, specific coverage and tier placement vary by plan. Check with your specific Part D plan for formulary details.

Where does this Medicare spending data come from?

All Medicare Part D spending data comes from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Spending by Drug dataset, which is publicly available at data.cms.gov.

Explore More Data Tools

For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.

Year

Total Spending

Claims

Beneficiaries

Cost/Unit

2019

N/A

2020

N/A

2021

N/A

2022

N/A

2023